Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1
Authors:
- 30 June 2017
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 56 (10) , 2267-2278
Abstract
Fas signaling promotes colorectal cancer (CRC) metastasis by inducing epithelial‐mesenchymal transition (EMT). The acquisition of EMT properties in turn induces stemness but the mechanism by which Fas signaling contributes to it still remains unclear. Hence, the aim of this study was to investigate how Fas signaling regulates CRC stemness. For this purpose, soft agar assay, sphere formation assay, cell survival analysis, immunoblot, qRT‐PCR, chromatin immunoprecipitation, and luciferase reporter assay were performed. Expression of FasL, Bmi1, and the miR‐200c in CRC specimens was examined through immunohistochemistry, qRT‐PCR, and immunoblot. In our study, Fas signaling induced stem cell properties in CRC specimens, relying on ERK1/2 MAPK pathway, with Bmi1 being mainly responsible for FasL‐induced stemness. FasL treatment promoted Bmi1 expression by inhibiting miR‐200c, which targets Bmi1 3′UTR region. Furthermore, FasL‐induced Zeb1 binded with miR‐200c promoter and inhibited its expression. Moreover, FasL‐induced β‐catenin nuclear expression promoted Zeb1 expression by binding with Zeb1 promoter. GSK‐3β, which regulates β‐catenin, was inhibited by FasL‐induced ERK1/2 MAPK signaling. Finally, FasL and Bmi1 expression in clinical samples increased during CRC progression, and a positive correlation between them was observed. Patients with high FasL and Bmi1 expression had a worse prognosis than patients with low expression. In conclusion, our results showed that Fas signaling can promote stemness in CRC through the modulation of Bmi1 expression via the ERK1/2 MAPK/GSK‐3β/β‐catenin/Zeb1/miR‐200c axis, suggesting that Fas signaling‐based cancer therapies should be administered cautiously, as the activation of this pathway not only leads to apoptosis but also induces stemness in CRC.Keywords
Funding Information
- National Natural Science Foundation of China (81472320)
This publication has 30 references indexed in Scilit:
- β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasivenessProceedings of the National Academy of Sciences, 2011
- BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancerInternational Journal of Cancer, 2011
- CD95 promotes tumour growthNature, 2010
- Causes and consequences of microRNA dysregulation in cancerNature Reviews Genetics, 2009
- Association of Inflammation-Related and microRNA Gene Expression with Cancer-Specific Mortality of Colon AdenocarcinomaClinical Cancer Research, 2009
- Regulation of Stem Cell Pluripotency and Differentiation Involves a Mutual Regulatory Circuit of the Nanog, OCT4, and SOX2 Pluripotency Transcription Factors With Polycomb Repressive Complexes and Stem Cell microRNAsStem Cells and Development, 2009
- Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem CellsCell, 2009
- Targeting of the Bmi-1 Oncogene/Stem Cell Renewal Factor by MicroRNA-128 Inhibits Glioma Proliferation and Self-RenewalCancer Research, 2008
- A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cellsEMBO Reports, 2008
- Phenotypic characterization of human colorectal cancer stem cellsProceedings of the National Academy of Sciences, 2007